#ASH24: Indolent B-cell NHL

To update you on the exciting content presented at the 66th American Society of Hematology (ASH) Meeting and Exposition, Dec 7–10, 2024, San Diego, US, we have collated our social media coverage. Catch up with our live social media relating to indolent B-cell non-Hodgkin lymphoma (NHL), here.

CONGRESS | #ASH24 | PRESENTATION
Lorenzo Falchi @MSKCancerCenter presented primary analysis outcomes of the phase II MITHIC-FL1 trial of mosunetuzumab in patients with newly diagnosed high-burden FL. Fixed-duration mosunetuzumab showed promising efficacy and a tolerable safety… pic.twitter.com/MBBv6URcgS

— Lymphoma Hub (@lymphomahub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION
Dylan Gagler, @Perlmutter_CC @nyulangone discussed a single-cell multiomic analysis on flow sorted CD19+/CD3- mature B-cells from 13 MYD88-mutated patients with Waldenstrom's macroglobulinemia.
The analysis revealed two WM subtypes— memory B-cell… pic.twitter.com/jz2e2zj032

— Lymphoma Hub (@lymphomahub) December 12, 2024

CONGRESS #ASH24 | LBA
Laurie Sehn, BC Cancer Centre for Lymphoid Cancer, discussed results from the phase III inMIND study, of tafasitamab + Len + R for R/R FL. Median PFS was higher in the Taf arm (22.4 mo) vs placebo (13.9 mo) and the study met the primary endpoint, this was… pic.twitter.com/MNDzlL7SvJ

— Lymphoma Hub (@lymphomahub) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Sattva S. Neelapu @MDAndersonNews shared 5-year follow-up data from the phase II ZUMA-5 trial of axi-cel in patients with R/R indolent NHL.
After a median follow-up of >5 years, axi-cel continued to demonstrate durable responses. With a median… pic.twitter.com/f84V9mvAVO

— Lymphoma Hub (@lymphomahub) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Tae Min Kim @snuh_official shared results from the phase II ELM-2 trial of odronextamab in heavily pretreated patients with R/R MZL.
Odronextamab showed promising efficacy, with an ORR of 77.1%, CR rate of 77.1%, 12-month DoR, PFS, and OS were… pic.twitter.com/LKOkx7fCma

— Lymphoma Hub (@lymphomahub) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Sikander Ailawadhi @MayoClinic shared results from the phase II CLOVER-WaM trial of Iopofosine I 131, in previously treated Waldenström's macroglobulinemia.
Iopofosine I 131 demonstrated promising efficacy, with a MRR of 58.2%, ORR of 83.6% and a… pic.twitter.com/oOe27YacpD

— Lymphoma Hub (@lymphomahub) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
John F. Seymour, @UniMelb shared data from the phase I CaDAnCe-101 trial of BGB-16673, a BTK degrader, in R/R Waldenström's macroglobulinemia (WM). BGB-16673 demonstrated a tolerable safety profile and promising antitumor activity in heavily… pic.twitter.com/1sbnrHCaZt

— Lymphoma Hub (@lymphomahub) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Christian Buske, University Hospital Ulm shared data from the phase II ECWM-2 trial of bortezomib plus ibrutinib/rituximab (B-IR) in first-line Waldenström's macroglobulinemia (WM).
B-IR showed showed promising efficacy and a tolerable safety… pic.twitter.com/9WbxqK2vzC

— Lymphoma Hub (@lymphomahub) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Noriko Fukuhara, Tohoku University Graduate School of Medicine presented data from the phase III JCOG1411/Flora trial of watchful waiting (WW) vs. rituximab as 1L treatment in patients with advanced stage low tumor burden follicular #lymphoma. EFS… pic.twitter.com/ak6tI6YlPl

— Lymphoma Hub (@lymphomahub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION@JuanAlderuccio @SylvesterCancer shares results from a phase II trial of loncastuximab with rituximab in patients with high-risk R/R FL.
Fixed-duration loncastuximab with rituximab showed promising efficacy and a tolerable safety profile, with… pic.twitter.com/PNOaXCGkoZ

— Lymphoma Hub (@lymphomahub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION
Marie José Kersten @Kersten_MJ @amsterdamumc highlights results from the ongoing phase I/II ATALANTA-1 trial.
GLPG5101 CAR T-cell therapy demonstrated promising efficacy, with CR rates of 100%, 95%, and 54% in patients with R/R MCL, R/R FL/MZL,… pic.twitter.com/byjxMV5MgS

— Lymphoma Hub (@lymphomahub) December 7, 2024

CONGRESS | #ASH24 | POSTER |@ShirleyPDSa @uclh shares the long-term results from patients with WM, treated with zanubrutinib as part of the phase III ASPEN study.
With a median FU of 5.8 years, zanubrutinib demonstrated durable responses, along with a favorable tolerability and… pic.twitter.com/BE3yjcaZwC

— Lymphoma Hub (@lymphomahub) December 13, 2024

CONGRESS | #ASH24 | POSTER
Catherine Thieblemont @HopSaintLouis presented 4-year updates from the phase II ELARA trial of Tisagenlecleucel in high-risk R/R FL.
Tisagenlecleucel continues to demonstrate robust durable responses >4 years post infusion, and a favorable safety… pic.twitter.com/0qHSthgOv2

— Lymphoma Hub (@lymphomahub) December 12, 2024

CONGRESS | #ASH24 | POSTER
Pier Luigi Zinzani, @UniboMagazine, shared data from the phase II BELLWAVE-003 trial of nemtabrutinib in R/R MZL.
Nemtabrutinib demonstrated promising efficacy, with an ORR of 64% and CR rate of 27% in a heavily refractory population of patients with… pic.twitter.com/XrcyHjUd9g

— Lymphoma Hub (@lymphomahub) December 12, 2024

CONGRESS | #ASH24 | POSTER
Nancy L. Bartlett, Washington University School of Medicine presented primary analysis outcomes of the pivotal phase II trial of mosunetuzumab (SC vs IV) in R/R FL.
Fixed-duration SC mosunetuzumab achieved high rates of deep and durable responses in… pic.twitter.com/dBz9zFT09s

— Lymphoma Hub (@lymphomahub) December 11, 2024

CONGRESS | #ASH24 | POSTER
Mazyar Shadman @mshadman, @fredhutch, shared 4-year follow-up results from a pivotal phase II trial (NCT02500407) of mosunetuzumab in heavily pretreated patients with R/R follicular #lymphoma. The ORR and CR rates were 77.8% and 60%, respectively, in… pic.twitter.com/vIBVViLsEr

— Lymphoma Hub (@lymphomahub) December 11, 2024

CONGRESS | #ASH24 | POSTER
Adam J Olszewski, @BrownUniversity discussed the interim analysis data of the phase II BrUOG-401 study of mosunetuzumab with response-driven lenalidomide augmentation in 1L follicular or marginal zone #lymphoma.
Fixed-duration SC mosunetuzumab achieved… pic.twitter.com/4LnZU5fKlG

— Lymphoma Hub (@lymphomahub) December 11, 2024

CONGRESS | #ASH24 | POSTER@JoshuaBrodyMD, @TischCancer discussed the early results from the Arm 3 of the EPCORE NHL-2 trial.
Fixed-duration SC epcoritamab with bendamustine + rituximab showed deep and durable responses, with both ORR and CR rate of 96% in first-line treatment… pic.twitter.com/sKQ8I6Ld9L

— Lymphoma Hub (@lymphomahub) December 11, 2024

CONGRESS | #ASH24 | PRESENTATION
Lorenzo Falchi @MSKCancerCenter shared 2- year follow-up data from the Arm 2 of the EPCORE NHL-2 trial of epcoritamab + rituximab + lenalidomide in R/R FL. Fixed-duration epcoritamab + rituximab + lenalidomide continued to show deep and durable… pic.twitter.com/8gHqyQjfDf

— Lymphoma Hub (@lymphomahub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION
Simone Ferrero at University of Torino presented data from the MRD-driven phase III FOLL12 trial comparing conventional rituximab maintenance (after R-CHOP or BR) vs a combined PET/MRD response-adapted post-induction approach in FL. MRD monitoring… pic.twitter.com/G7pB5oHTmQ

— Lymphoma Hub (@lymphomahub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION@araujo_ferran of Institut D’Investigacions Biomèdiques August Pi I Sunyer discussed the prognosis potential of CD70 and its biological role in patients with FL and development of a novel dual CD19-CD70 CAR T-cell therapy for FL and B-NHL.
Follow… pic.twitter.com/S1xb1lk3Wu

— Lymphoma Hub (@lymphomahub) December 8, 2024